Trial Search Results
Expanded Access to Ensartinib for Participants With ALK+ NSCLC
This is an open-label, multicenter, intermediate-sized expanded access treatment protocol to the existing IND 111,695 for ensartinib (X-396). The treatment plan is designed to provide ensartinib to participants with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
Stanford is currently not accepting patients for this trial.
Xcovery Holding Company, LLC
- Drug: Ensartinib
1. Adult patients (>18 years-of-age) with advanced ALK-positive NSCLC as determined by an
FDA approved test.
2. Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1.
3. Informed consent must be provided by each patient.
4. Patient is not eligible or does not have access for participation in any of the other
ongoing clinical trials for ensartinib.
5. Ability to swallow and retain oral medication.
6. Male and female patients must agree to abstain or to use two highly effective forms of
contraception during the treatment period and for 90 days after the last dose of study
7. Adequate organ system function.
8. Patients with treated CNS metastases are eligible if they are asymptomatic with
respect to the CNS metastases and do not require escalating doses of systemic
corticosteroids. ALK-positive patients with untreated CNS lesions may be allowed to
enroll as long as the patients are asymptomatic with respect to the CNS metastases and
do not require systemic corticosteroids or anticonvulsants.
1. Patients currently receiving cancer therapy.
2. Use of an investigational or targeted drug within 21 days or 5 half-lives (whichever
is shorter) prior to the first dose of ensartinib. A minimum of 10 days between
termination of the treatment and administration of ensartinib is required. However, in
the case of ALK TKIs, a 2-day window between termination of the TKI and the start of
ensartinib is allowed. In addition, any drug-related toxicity should have recovered to
Grade 1 or less, with the exception of alopecia.
3. Any major surgery or immunotherapy within the last 21 days (focal radiation does not
require a washout period; ≥4 weeks for whole brain radiotherapy). Chemotherapy
regimens with delayed toxicity within the last 4 weeks (or within the last 6 weeks for
prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a
weekly basis with limited potential for delayed toxicity within the last 2 weeks.
4. Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically
related to ensartinib (e.g., crizotinib) or to the active ingredient of ensartinib or
to tartrazine, a dye used in the ensartinib 100 mg capsules.
5. Patients receiving CYP3A substrates with narrow therapeutic indices, strong CYP3A
inhibitors, and strong CYP3A inducers.
6. Presence of active gastrointestinal (GI) disease or other condition that will
interfere significantly with the absorption, distribution, metabolism, or excretion of
7. Clinically significant cardiovascular disease.
8. Patients who are immunosuppressed (including known HIV infection), have a serious
active infection at the time of treatment, have known hepatitis C, or have any serious
underlying medical condition that would impair the ability of the patient to receive
9. Psychological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol.
10. Have a history or the presence at baseline of pulmonary interstitial lung disease,
drug-related pneumonitis, or radiation pneumonitis.
11. Females who are pregnant or breastfeeding.
12. Patient with any concurrent condition or receiving any concurrent medication that, in
the investigator's opinion, would impart excessive risk associated with study
participation or otherwise make it inappropriate for the patient to participate.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study